I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

By Reuters March 30, 20209:10 PM UTCUpdated ago March 30 (Reuters) - Akero Therapeutics Inc: * AKERO THERAPEUTICS TO ANNOUNCE RESULTS FOR WEEK 12 EFFICACY ENDPOINTS FROM NASH PHASE 2A BALANCED ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH.

Akero Therapeutics, Inc. (NASDAQ:AKRO) is up 71.75% year-to-date. Overall AKRO ranks 4th on our list of the biotech stocks that are skyrocketing so far in 2025.

Akero Therapeutics Announces Proposed Public Offering Of Common Stock By Reuters July 6, 20204:01 AM PDTUpdated 4 years ago ...